Liprolog Kwikpen (Insulin Lispro)

Insulin lispro mimics natural insulin by binding to insulin receptors on muscle, fat and liver cells, stimulating glucose uptake and storage while inhibiting hepatic glucose production. Its altered amino‑acid sequence allows it to dissociate quickly from hexamers, resulting in rapid absorption after subcutaneous injection and a fast onset of action.

The dose of insulin lispro is individualized; a qualified healthcare professional determines the amount, timing and frequency based on the patient’s blood‑glucose readings, carbohydrate intake, lifestyle and overall treatment plan. Patients should follow the prescriber’s instructions and adjust only under medical guidance.

Insulin lispro is classified as pregnancy category B, indicating that animal studies have not shown risk and there are no adequate human studies. It may be used during pregnancy or lactation when the anticipated benefit justifies the potential risk, and only under the supervision of a healthcare provider.

To request Liprolog Kwikpen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Liprolog Kwikpen delivers insulin lispro, which has a rapid onset (≈15 minutes) and short duration (≈3–5 hours), similar to other rapid‑acting analogues such as insulin aspart or glulisine. Choice among them often depends on physician preference, patient response, device convenience and formulary considerations rather than major efficacy differences.

Unopened pens should be stored in a refrigerator at 2–8 °C, protected from light and not frozen. Once in use, the pen may be kept at controlled room temperature (≤30 °C) for up to 28 days, but should always be kept away from direct heat and extreme cold. Do not shake the pen before use.

Liprolog Kwikpen is a pre‑filled, disposable pen designed for subcutaneous injection. After selecting the prescribed dose, the user primes the pen, inserts a new needle, and injects into the abdomen, thigh or upper arm at a 90° angle. Proper technique and rotation of injection sites help minimize local reactions.

The most critical risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and allergic reactions ranging from urticaria to anaphylaxis. Patients should be educated to recognize early signs, have rapid‑acting carbohydrate on hand, and seek immediate medical attention if a serious reaction occurs.

Liprolog Kwikpen should be avoided in individuals with a known hypersensitivity to insulin lispro or any excipients in the formulation. It is also contraindicated in patients experiencing hypoglycemia unawareness without appropriate supervision, and in those for whom rapid‑acting insulin is not indicated by their treating physician.